About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

339,504 studies
in
214 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/01/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/01/2020.

Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

Clinicaltrials.gov identifier NCT03118466

Recruitment Status Recruiting

First Posted April 18, 2017

Last update posted June 26, 2019

Study Description

Brief summary:

This research study is evaluating how a drug called lenalidomide, given in combination with the standard chemotherapy regimen of Mitoxantrone, Etoposide, and Cytarabine, commonly referred to as MEC, works in individuals with either relapsed or refractory AML

  • Condition or Disease:AML
  • Intervention/Treatment: Drug: Etoposide
    Drug: Cytarabine
    Drug: Lenalidomide
    Drug: Mitoxantrone
  • Phase: Phase 2
Detailed Description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied. The FDA (the U.S. Food and Drug Administration) has not approved lenalidomide for this specific disease, but it has been approved for other uses, including for patients with multiple myeloma and some patients with myelodysplastic syndrome. This treatment is investigational because it is not approved by the FDA for patients with AML. Lenalidomide is a chemotherapy that also modulates the immune system, and is in a category of drugs called immunomodulatory drugs or IMIDs. Some research studies suggest that lenalidomide may be effective in patients with AML. Since the investigators know that many patients who receive MEC chemotherapy alone have less than desired response rates and overall shorter periods of remission (time free from leukemia) after treatment, the investigators are studying whether the addition of lenalidomide to MEC improves upon typical responses. The combination of MEC (mitoxantrone, etoposide, and cytarabine) is a standard treatment option, commonly used for relapsed or refractory acute myeloid leukemia. .

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 40 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia
  • Actual Study Start Date: September 2017
  • Estimated Primary Completion Date: September 2020
  • Estimated Study Completion Date: September 2024
Arms and interventions
Arm Intervention/treatment
Experimental: Lenalidomide and MEC chemotherapy
Lenalidomide is taken orally on a daily basis days 1-10. Mitoxantrone, Etoposide, and Cytarabine are administered intravenously on a daily basis for days 4 through 8 of the treatment. There is only one cycle of treatment in this study.
Drug: Etoposide
A Drug that interfere with the action of topoisomerase enzymes (topoisomerase I and II). Topoisomerase enzymes control the manipulation of the structure of DNA necessary for replication.

Drug: Cytarabine
Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA.

Drug: Lenalidomide
It may act by inhibiting the growth of new blood vessels (angiogenesis) in tumors, enhancing the status of the immune system, or decreasing cytokine and growth factor production

Drug: Mitoxantrone
It interfere with cell reproduction
Outcome Measures
  • Primary Outcome Measures: 1. Complete Response Rate [ Time Frame: up to 45 days ]
    Proportion of patients who have no apparent leukemia and have normal blood counts after treatment
  • Secondary Outcome Measures: 1. Days to ANC recovery [ Time Frame: up to 45 days ]
    Time from the first day of chemotherapy to the first day where the neutrophil count is > 500 for 3 days
  • 2. Days of platelet recovery [ Time Frame: up to 45 days ]
    Time from the first day of chemotherapy to the first day where the platelet count is stable > 20 for 3 days
  • 3. Treatment-related mortality [ Time Frame: 50 days ]
    Cumulative number of deaths not related to persistent or relapsed leukemia during treatment
  • 4. Transfusion support: Number of red blood cell and platelet transfusions [ Time Frame: 45 days ]
    Number of red blood cell and platelet transfusions
  • 5. Explore Associations Between Somatic Mutations and CR [ Time Frame: Up to 45 days ]
    The proportion of patients achieving remission according to mutation status
Eligibility Criteria
  • Ages Eligible for Study: 18 to 70 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Acute myelogenous leukemia diagnosed by WHO criteria with one of the following
(patients with biphenotypic leukemia are eligible, provided that the treating
physician determines an AML treatment regimen is appropriate)

- Primary refractory disease following > 1cycle of chemotherapy, (such as
hypomethylating agent or induction chemotherapy)

- First relapse or higher. Patients with primary or secondary acute myelogenous
leukemia are eligible.

- Age 18-70 years old

- LVEF > 50 %

- ECOG Performance status 0-2

- Able to adhere to study schedule and other protocol requirements.

- Participants must have normal organ function as defined below, unless felt due to
underlying disease and approved by the overall PI. Patients with Gilbert's disease may
have total bilirubin up to < 3 x ULN. - Creatinine < 2.0mg/dl - Total bilirubin < 1.5 x ULN - AST (SGOT) and ALT (SGPT) < 3 x ULN. - Patients may receive hydroxyurea, steroids, or leukapheresis as necessary until Day 5 of treatment. - Patients must give voluntary written informed consent and HIPAA authorization before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. - Patients may have had prior treatment for MDS or AML, including prior lenalidomide for MDS or AML or another condition. - Patient may have had prior autologous or allogeneic transplant (family member, unrelated donor, or cord blood) if there is at least 90 days between transplant and study entry. - Patients may also have had donor lymphocyte infusion if there is at least 60 days between donor lymphocyte infusion and study entry. - Patients on immunosuppression are also eligible. - Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL prior to receiving treatment with lenalidomide, and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. - Ability to understand and the willingness to sign a written informed consent document. - All study participants must be registered into the mandatory Revlimid REMS ® program, and be willing and able to comply with the requirements of the REMs ® program. Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program Exclusion Criteria: - Known hypersensitivity to thalidomide or lenalidomide (if applicable). - The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs. - Known seropositive for human immunodeficiency virus (HIV). HIV testing is not required. Hepatitis testing is not required. - Patients who have had a myocardial infarction within 6 months of enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. - Any serious medical condition laboratory abnormality or psychiatric illness that would prevent the subject from signing the consent form. - Any condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. - Patients with major surgery within 28 days prior to treatment. - Patients with any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol. - Patient has received an investigational agent or cytotoxic chemotherapy (excluding hydroxyurea) within 7 days of study entry. - Patients with acute promyelocytic leukemia. - Females who are pregnant

Contacts and Locations
Contacts

Contact: Andrew Brunner, MD 617-724-1124 Andrew_Brunner@DFCI.HARVARD.EDU

Locations

United States, Massachusetts
Dana Farber Cancer Institute
Boston

United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston

United States, Massachusetts
Massachusetts general Hospital
Boston

Sponsors and Collaborators

Massachusetts General Hospital

Celgene

Investigators

Principal Investigator: Andrew Brunner, MD Massachusetts General Hospital

More Information
  • Responsible Party: Massachusetts General Hospital
  • ClinicalTrials.gov Identifier: NCT03118466 History of Changes
  • Other Study ID Numbers: 16-574
  • First Posted: April 18, 2017 Key Record Dates
  • Last Update Posted: June 26, 2019
  • Last Verified: June 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Massachusetts General Hospital: AML
  • Additional relevant MeSH terms: Leukemia, Myeloid, Acute